Skip to Content

Zimmer Biomet Holdings Inc ZBH Stock Quote

| Rating as of


Last close prices updated as of Jun 09, 2023, 7:00 PM EST | USD | BATS BZX Real-Time Price
  • Last Close 136.01
  • Sector Healthcare
  • Industry Medical Devices
  • Investment Style Mid Blend
  • Day Range 134.22  –  136.35
  • Year Range 100.39  –  149.25
  • Market Cap 28.3675 Bil
  • Volume / Avg 1.3 Mil /  1.4 Mil
  • Price / Sales 4.03
  • Price / Book 2.33
  • Forward Div Yield 0.71%
  • Trailing Div Yield 0.88%

Morningstar‘s Stock Analysis ZBH

Currency in
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


Zimmer Biomet Earnings: Strong First Quarter Bodes Well for 2023

Debbie S. Wang Senior Equity Analyst

Analyst Note

| Debbie Wang |

Wide-moat Zimmer Biomet delivered first-quarter results that exceeded most expectations, especially on the top line, and we've slightly dialed up our projections for the full year following this strength. However, these adjustments weren't enough to materially shift our fair value estimate, especially as the firm's first-quarter costs tracked closely along with our expectations. Zimmer Biomet's quarterly revenue growth of 13% (in constant currency) was within spitting distance of Stryker's 14% year-over-year growth. Similar to the cardiac device makers, most of the large orthopedic implant competitors received a boost from the comparison with a soft prior-year period. But even after accounting for that, the device makers saw robust quarterly growth thanks to increased medical utilization, easing labor conditions at providers, and improving access to component parts. Though we think it's unlikely that Zimmer Biomet can maintain this 13% growth through the full year, the strong start does suggest our original low-single-digit revenue growth assumption in 2023 was likely too low. We now estimate full-year sales growth should fall closer to 4.7%, after adjusting for foreign exchange headwinds.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics ZBH

Company Profile ZBH

Business Description

Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.

345 East Main Street
Warsaw, IN, 46580
Industry Medical Devices
Employees 18,000

Related Articles ZBH

Morningstar analysts hand-select direct competitors or comparable companies to provide context on the strength and durability of ZBH’s competitive advantage.

Zimmer Biomet Holdings Inc


Johnson & Johnson


Stryker Corp


Smith & Nephew PLC

+$0.72 (0.53%) −$0.25 (0.16%) +$3.87 (1.40%) +$2.00 (0.17%)
Market Cap
28.37 Bil415.82 Bil106.53 Bil1.04 Tril
Medical Devices Drug Manufacturers - General Medical Devices Medical Devices

* Trading data in this section is delayed by at least 15 minutes.

FAQs for Zimmer Biomet Holdings Inc Stock

Yes. ZBH has a forward dividend yield of 0.71%. See ZBH’s full dividends and stock split history on the Dividend tab.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

Learn more about dividend yield.

ZBH’s market cap is 28.37 Bil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.

Learn more about market capitalization.

ZBH’s stock style is Mid Core.
Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.

High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.

Learn more about style.

ZBH’s price/sales is 4.03.
Price/sales represents the amount an investor is willing to pay for a dollar generated from a particular company’s sales or revenues.

ZBH’s price/forward earnings is 63.56.
Forward P/E gives some indication of how cheap or expensive a stock is compared with consensus earnings estimates. The lower the Forward P/E, the cheaper the stock.

ZBH’s price/book is 2.33.
Price/book ratio can tell investors approximately how much they’re paying for a company’s assets, based on historical, rather than current, valuations. Historical valuations generally do not reflect a company’s current market value. Value investors frequently look for companies that have low price/book ratios.

See ZBH’s valuation ratios compared to the Market Index.

ZBH’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

Compare ZBH’s historical performance against its industry peers and the overall market.